US officials have given the green light to a new drug for Alzheimer’s disease, expanding the available treatment options for people in the early stages of brain decline. The US Food and Drug Administration (FDA) approved Eli Lilly’s donanemab, which is sold under the brand name Kisunla. It comes weeks after a panel of independent advisors to the FDA voted June 10 to endorse Eli Lilly’s experimental Alzheimer’s medication, finding that the drug is effective, and the benefits outweigh the risks. “Alzheimer’s disease is a devastating disease for the person diagnosed and their loved ones,” said Te…
